Active Ingredient(s): Bictegravir + Emtricitabine + Tenofovir Alafenamide
FDA Approved: * February 7, 2018
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Biktarvy Overview

Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is an antiviral drug of the integrase inhibitor class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016.[3] In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for t...

Read more Biktarvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Biktarvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Bictegravir + Emtricitabine + Tenofovir Alafenamide
  • Tablet: 50mg + 200mg + 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Biktarvy: (2 results)

Sorted by National Drug Code
  • 61958-2501 Biktarvy Oral Tablet by Gilead Sciences, Inc.
  • 70518-3080 Biktarvy Oral Tablet by Remedyrepack Inc.

Drugs with one or more similar ingredients: (18 results)